A comprehensive public health approach to address the burden of renal disease in Singapore

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Ramirez, Sylvia Paz B ^a,b  

^a National Kidney Foundation   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMMUNITY CARE; CONFERENCE PAPER; CONTINUING EDUCATION; EARLY DIAGNOSIS; EPIDEMIC; FEMALE; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEALTH SERVICE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTCOMES RESEARCH; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; RACE DIFFERENCE; RISK ASSESSMENT; SECONDARY PREVENTION; SINGAPORE; TECHNIQUE;

EID: 0037530407     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.asn.0000070154.00058.b4     Document Type: Conference Paper

References (37)

1. US Renal Data System: International comparisons of ESRD therapy. In: USRDS 1999 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases. United States Renal Data System Coordinating Center, 1999, pp 173-184
2. Iseki K: The Okinawa screening program. J Am Soc Nephrol 14: S127-S130, 2003
3. Ohmit SE, Flack JM, Peters RM, Brown WW, Grimm R: Longitudinal Study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP), this supplement
4. Hostetter TH, Lising M: National Kidney Disease Education Program, this supplement
5. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI): clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39[Suppl 2]: S1-S246, 2002
6. Ramirez SPB, Hsu SIH, Nandakumar M, Friedman EA, Durai TT, Owen WF: Funding ESRD care through charity: The paradigm of the National Kidney Foundation of Singapore. Semin Nephrol 21: 411-418, 2001
7. Ramirez SPB, Hsu SIH, McClellan W: Taking a public health approach to prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int 63[Suppl 83]: S61-S65, 2003
8. Buehler JW: Surveillance. In: Modern Epidemiology, 2nd: Ed., edited by Rothman KJ, Greenland S, Philadelphia, Lippincot, Raven, 1998, pp 435-457
9. Morrison AS: Screening, In: Modern Epidemiology, 2nd Ed., edited by Rothman KJ, Greenland S, Philadelphia, Lippincot, Raven, 1998, pp 499-518
10. Engelgau MM, Venkat Narayan KM, Herman W: Screening for type 2 diabetes. Diabetes Care 23: 1563-1580, 2000
11. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Survey. Am J Kidney Dis 32: 992-999, 1998
12. McClellan WM, Knight DF, Karp H, Brown WW: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis 29: 368-375, 1997
13. American Diabetes Association: Clinical practice recommendations 2001. Diabetes Care 24[Suppl 1]: S69-S72, 2001
14. Keane WF, Kenoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33: 1004-1010, 1999
15. Davidson MB, Smiley JF: Relationship between dipstick positive proteinuria and albumin: creatinine ratios. J Diabetes Complications 13: 52-55, 1999
16. Grimm RH, Svendsen KH, Kasiske B, Keane WF, Wahi MM, for the MRFIT Research Group: Proteinuria is a risk factor for mortality over 10 years of follow-up. Kidney Int 52[Suppl 63]: S10-S14, 1997
17. Weinstock Brown WW, Keane WF: Proteinuria and cardiovascular disease. Am J Kidney Dis 38[Suppl 1]: S8-S13, 2001
18. Taal MW, Brenner BM: Achieving maximal renal protection in nodiabetic chronic renal disease. Am J Kidney Dis 38: 1365-1371, 2001
19. Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia: ACE inhibitors to prevent endstage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN Trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12: 2832-2837, 2001
20. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, deJong PE, deZeeuw D, Sahhinfar S, Ruggenenti P, Remuzzi G, Levey AS: AIPRD Study Group. Angiotensin Converting Enzyme Inhibition and Progression of Renal Disease. Kidney Int 60: 1131-1140, 2001
21. Scheid DC, McCarthy LH, Lawler FH, Hamm RM, Reilly KE: Screening for microalbumuria to prevent nephropathy in patients with diabetes: A systematic review of the evidence. J Fam Pract 50: 661-668, 2001
22. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin converting enzyme inhibitors. Ann Int Med 131: 660-667
23. Craig JC, Barratt A, Cumming R, Irwig L, Salkeld G: Feasibility study of the early detection and treatment of renal disease by mass screening. Int Med J 32: 6-14, 2002
24. Rose G: Prevention for individuals and the high-risk strategy. In: The Strategy of Preventive Medicine, edited by Rose G, Oxford, UK, Oxford University Press, 1992, pp 29-52
25. Rose G: The population strategy of prevention. In: The Strategy of Preventive Medicine, edited by Rose G, Oxford, UK, Oxford University Press, 1992, pp 95-106
26. Ramirez SPB, McClellan W, Port FK, Hsu SIH: Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol 13: 1907-1917, 2002
27. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
28. Woo KT, Lee GSL: First report of the Singapore Renal Registry 1997, Singapore Continental Press Pte Ltd., 1998
29. Ramirez SPB, McClellan W, Port FK, Hsu SIH: The effectiveness of population-based strategies in screening for proteinuria and hypertension in a large Asian population. J Am Soc Nephrol 13: 612A, 2002
30. Ministry of Health, Singapore: National Health Survey, 1998, Singapore, Ministry of Health, 1999
31. Parving HH: Diabetic nephropathy: Prevention and treatment. Kidney Int 60: 2041-2055, 2001
32. Klonoff DC, Schwartz DM: An economic analysis of interventions for diabetes. Diabetes Care 23: 390-404, 2000
33. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47: 1703-1720, 1995
34. Ministry of Health, Singapore: Health Care Expenditure and Financing, in the Annual Report 97/98, Singapore, Singapore National Printers Ltd., 1998; pp 18-25
35. Rith-Najarian S, Ross C, Branchaud C, Ghodes D, Acton K, Simonson G, Weaver T, Bradley R, Mazze R: Improving glycemic control in Native American Communities. Staged diabetes management versus standard care [Abstract]. Diabetes 48[Suppl 1]: A193, 1999
36. Mazze RS, Simonson G, Strock E, Bergenstal R, Idrogo M, Ramirez S, Hsu S, and the International SDM Study Group. Staged Diabetes Management, a systematic evidence-based approach to the prevention and treatment of diabetes and its comorbidities. Pract Diab Int Suppl 18: S1-S16, 2001
37. Rubin RJ, Dietrick KA, Hawk AD: Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 83: 2635-2642, 1998